knowledge -WSS

knowledge

author：leisure time 2025-08-26 03:42:25 - browse：48

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： UnitedHealth CEO's Medicaid comments send insurer stocks diving

knowledge

focus

WSS

Take antibiotics after sex, CDC recommends for certain risk groups

Structure Therapeutics oral GLP

ThunderShirts, dance parties and anxiety meds can help ease dogs' July Fourth dread

Russians and Belarusians back at Wimbledon as war in Ukraine continues

BD to buy Edwards patient monitoring unit for $4.2 billion

The most pressing bird flu mysteries scientists want answered

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

How one medical school became remarkably diverse

10 states plan to sue EPA over standards for residential wood

Anesthesiologist group: stop taking Ozempic before surgery

Sutter Health’s antitrust win overturned by appeals court

George Santos makes 1st court appearance after pleading not guilty to 13 counts

US ambassador visits Wall Street Journal reporter detained in Russia on charges of espionage

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Trump pressured former Arizona governor to overturn 2020 election results: Sources

Sports medicine is finally prioritizing gender equality

Ukraine holds disaster drills amid fears Russia could sabotage nuclear power plant

leisure time

EU climate chief is concerned over the expansion of the coal industry in China

Ukraine holds disaster drills amid fears Russia could sabotage nuclear power plant

Legitimacy of 'customer' in Supreme Court gay rights case raises ethical, legal flags

Eli Lilly’s Zepbound improved liver scarring in mid

Finland to offer bird flu vaccine to select groups of people, a possible global first

Michigan man accused of striking an officer during the US Capitol attack is arrested in Florida

knowledge

hotspot

focus

leisure time